Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P860 | DOI: 10.1530/endoabs.35.P860

ECE2014 Poster Presentations Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) (108 abstracts)

Evolution of glucose tolerance status after treatment of acromegaly: a prospective study in 57 patients

Corinne Jonas , Orsalia Alexopoulou & Dominique Maiter

Department of Endocrinology and Nutrition, UCL St Luc Hospital, Brussels, Belgium.

Background: Acromegaly is frequently associated with impaired glucose tolerance (IGT) or diabetes and treatment has also differential effects on glucose metabolism depending on specific type of medication.

Objective: To study in 57 acromegalic patients evolution of glucose metabolism according to disease activity and treatment.

Methods: IGF1 measurement, oral glucose tolerance test (OGTT) and HOMA test to evaluate insulin sensitivity (HOMA-S) and β-cell function (HOMA-β) were performed in all patients at diagnosis and at last follow-up (median follow-up 7 years).

Results: At diagnosis of acromegaly, 14 patients (25%) were diabetic, 15 (26%) had IGT and 28 (49%) had normal GT. At the last visit, 32% were diabetic and 26% remained glucose intolerant. There was a decrease in fasting glucose (−10.4 mg/dl) in the 20 patients cured by surgery (group I), whereas it increased in the 28 patients controlled under medical therapy (group II, +5.5 mg/dl) and in the nine patients with active disease (group III, +8.8 mg/dl; P=0.016 vs group I). There was no significant difference in evolution of HbA1c and HOMA-S between groups, but loss of β function was more pronounced in groups II (−74.1±12.5%) and III (−38.7±6.4%) vs group I (−26.1±12.9%; mean±S.E.M.; P=0.035). Type of treatment influenced changes in HbA1c between diagnosis and last visit with a decrease (−1.7%) in patients under pegvisomant and an increase in patient treated by somatostatin analogs (+0.3%; P=0.044). In the cured patients, 30% had improved their GT status vs only 11% in the other groups, while deterioration was more frequently observed in patients with medical therapy.

Conclusions: This study shows that more than 50% of acromegalic patients have still IGT or diabetes at distance from diagnosis. Improvement of glucose metabolism is mainly observed in cured patients and in patients treated with pegvisomant.

Article tools

My recent searches

No recent searches.